|
|
|
| Kaixuan-Jiedu decoction ameliorates imiquimod-induced psoriasis-like skin lesions in mice by regulating S1P |
| QIN Yeping, DAI Dan, XIAO Xue, SONG Ping |
(Department of Dermatology, Guang′anmen Hospital, China Academy of Chinese Medical Sciences, Beijing 100053, China)
|
|
|
|
Abstract Objective： To investigate the effects of Kaixuan-Jiedu decoction (KXJD) on psoriasis-like mice model and its regulation of S1P. Methods： Twenty-five BALB/c mice were randomly and equally divided into normal group, model group, methotrexate group, KXJD-M and KXJD-H group. In addition to the normal group, the psoriasislike mice model were established by external application of imiquimod in other groups, and samples were taken after 7 days of continuous intervention. During the period, the skin lesions were photographed and the psoriasis area and severity index (PASI) score was calculated; HE staining was used to observe the pathological changes of skin lesions and measure the thickness of epidermis; the spleen and thymus were photographed and weighed; the expression of Ki67 and S1P in epidermis was detected by immunohistochemistry; Western blotting assay was used to detect the expression of KRT17, Claudin and Occludin in skin lesions; the mRNA levels of IL-17, IL-23 and S1PRs were detected by qRT-PCR. Results： Compared with the model group, KXJD could alleviate the psoriatic skin lesions, reduce the PASI score and epidermal hyperplasia (both P<0.01), improve the index of thymus and spleen and vascular proliferation (P<0.01 or P<0.05), reduce the mRNA expression of inflammatory factors IL-17 and IL-23 (P<0.01), and repair the skin barrier (P<0.05). Meanwhile, KXJD could downregulate the expression of S1P and S1PRs mRNA in epidermis (P<0.05). Conclusion： KXJD could alleviate the symptoms of local skin lesions in psoriasis, and its possible mechanism may be related with the regulation of S1P.
|
|
Received: 06 February 2023
|
|
|
|
［1］Tang L， Yang X， Liang Y， et al. Transcription factor retinoidrelated orphan receptor γt： a promising target for the treatment of psoriasis［J］. Front Immunol， 2018， 9： 1210.
［2］de Oliveira PS， Pereira MC， Silva de Paula SK， et al. Increased IL17A， IFNG， and FOXP3 transcripts in moderatesevere psoriasis： a major influence exerted by IL17A in disease severity［J］. Mediators Inflamm， 2016， 2016： 4395276.
［3］Parisi R， Symmons DP， Griffiths CE， et al. Global epidemiology of psoriasis： a systematic review of incidence and prevalence［J］. J Invest Dermatol, 2013， 133(2)： 377-385.
［4］Ding X， Wang T， Shen Y， et al. Prevalence of psoriasis in China： a populationbased study in six cities［J］. Eur J Dermatol， 2012， 22(5)： 663-667.
［5］Armstrong AW， Read C. Pathophysiology， clinical presentation， and treatment of psoriasis： a review［J］. JAMA， 2020， 323(19)： 1945-1960.
［6］Takeshita J， Grewal S， Langan SM， et al. Psoriasis and comorbid diseases： Epidemiology［J］. J Am Acad Dermatol， 2017， 76(3)： 377-390.
［7］Wang H， Wang Z， Rani PL， et al. Identification of PTPN22， ST6GAL1 and JAZF1 as psoriasis risk genes demonstrates shared pathogenesis between psoriasis and diabetes［J］. Exp Dermatol， 2017， 26(11)： 1112-1117.
［8］Parisi R， Iskandar IYK， Kontopantelis E， et al. National， regional， and worldwide epidemiology of psoriasis： systematic analysis and modelling study［J］. BMJ， 2020， 369： m1590.
［9］Nowowiejska J， Baran A， Flisiak I. Aberrations in lipid expression and metabolism in psoriasis［J］. Int J Mol Sci， 2021， 22(12)： 6561.
［10］代丹， 陈艳华， 何春燕， 等. 基于靶向脂质组学探究开玄补肾法对寻常型银屑病的干预机制［J］. 中国实验方剂学杂志， 2023， 29(4)： 117-125.
［11］Park JW， Park WJ， Futerman AH. Ceramide synthases as potential targets for therapeutic intervention in human diseases［J］. Biochim Biophys Acta， 2014， 1841(5)： 671-681.
［12］Hait NC， Oskeritzian CA， Paugh SW， et al. Sphingosine kinases， sphingosine 1phosphate， apoptosis and diseases［J］. Biochim Biophys Acta， 2006， 1758(12)： 2016-2026.
［13］Gardell SE， Dubin AE， Chun J. Emerging medicinal roles for lysophospholipid signaling［J］. Trends Mol Med， 2006， 12(2)： 65-75.
［14］Kozowska D， HarasimSymbor E， Mys＇liwiec H， et al. Serum sphingolipid level in psoriatic patients with obesity［J］. Postepy Dermatol Alergol， 2019， 36(6)： 714-721.
［15］Chun J， Giovannoni G， Hunter SF. Sphingosine 1phosphate receptor modulator therapy for multiple sclerosis： differential downstream receptor signalling and clinical profile effects［J］. Drugs， 2021， 81(2)： 207-231.
［16］宋坪， 王晓旭， 杨茂誉， 等. 开通玄府、通络解毒法治疗斑块状银屑病120例疗效观察［J］. 中医杂志， 2013， 54(17)： 1476-1479.
［17］Sun L, Guo X, Qin Y, et al. Serum intestinal metabolites are rised in patients with psoriasis and metabolic syndrome［J］. Clin Cosmet Investig Dermatol, 2022, 15: 879-886.
［18］Boehncke WH， Schn MP. Psoriasis［J］. Lancet， 2015， 386(9997)： 983-994.
［19］中华中医药学会皮肤科分会. 皮肤科分会银屑病中医治疗专家共识（2017年版）［J］. 中国中西医结合皮肤性病学杂志， 2018， 17(3)： 273-277.
［20］Borodzicz S， Rudnicka L， MirowskaGuzel D， et al. The role of epidermal sphingolipids in dermatologic diseases［J］. Lipids Health Dis， 2016， 15： 13.
［21］Dai D， He C， Wang S， et al. Toward personalized interventions for psoriasis vulgaris： molecular subtyping of patients by using a metabolomics approach［J］. Front Mol Biosci， 2022， 9： 945917.
［22］Matloubian M， Lo CG， Cinamon G， et al. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1［J］. Nature， 2004， 427(6972)： 355-360.
［23］Schwab SR， Pereira JP， Matloubian M， et al. Lymphocyte sequestration through S1P lyase inhibition and disruption of S1P gradients［J］. Science， 2005， 309(5741)： 1735-1739.
［24］Olsson T， Boster A， Fernández ， et al. Oral ponesimod in relapsingremitting multiple sclerosis： a randomised phase Ⅱ trial［J］. J Neurol Neurosurg Psychiatry， 2014， 85(11)： 1198-1208.
［25］Jin J， Xue N， Liu Y， et al. A novel S1P1 modulator IMMH002 ameliorates psoriasis in multiple animal models［J］. Acta Pharm Sin B， 2020， 10(2)： 276-288.
［26］Blankenbach KV， Schwalm S， Pfeilschifter J， et al. Sphingosine1phosphate receptor2 antagonists： therapeutic potential and potential risks［J］. Front Pharmacol， 2016， 7： 167.
［27］Mys＇liwiec H， Baran A， HarasimSymbor E， et al. Increase in circulating sphingosine1phosphate and decrease in ceramide levels in psoriatic patients［J］. Arch Dermatol Res， 2017， 309(2)： 79-86.
［28］Olesch C， Ringel C， Brüne B， et al. Beyond immune cell migration： the emerging role of the sphingosine1phosphate receptor S1PR4 as a modulator of innate immune cell activation［J］. Mediators Inflamm， 2017， 2017： 6059203.
［29］Kunkel GT， Maceyka M， Milstien S， et al. Targeting the sphingosine1phosphate axis in cancer， inflammation and beyond［J］. Nat Rev Drug Discov， 2013， 12(9)： 688-702.
［30］Aoki M， Aoki H， Ramanathan R， et al. Sphingosine1phosphate signaling in immune cells and inflammation： roles and therapeutic potential［J］. Mediators Inflamm， 2016， 2016： 8606878.
［31］van Doorn R， Lopes Pinheiro MA， Kooij G， et al. Sphingosine 1phosphate receptor 5 mediates the immune quiescence of the human brain endothelial barrier［J］. J Neuroinflammation， 2012， 9： 133.
［32］Moon SH， Kim JY， Song EH， et al. Altered levels of sphingosine and sphinganine in psoriatic epidermis［J］. Ann Dermatol， 2013， 25(3)： 321-326.
［33］Checa A， Xu N， Sar DG， et al. Circulating levels of sphingosine1phosphate are elevated in severe， but not mild psoriasis and are unresponsive to antiTNFα treatment［J］. Sci Rep， 2015， 5： 12017.
［34］Shin SH， Cho KA， Hahn S， et al. Inhibiting sphingosine kinase 2 derivedsphingosine1phosphate ameliorates psoriasislike skin disease via blocking Th17 differentiation of nave CD4 T lymphocytes in mice［J］. Acta Derm Venereol， 2019， 99(6)： 594-601.
［35］PérezJeldres T， Tyler CJ， Boyer JD， et al. Targeting cytokine signaling and lymphocyte traffic via small molecules in inflammatory bowel disease： JAK inhibitors and S1PR agonists［J］. Front Pharmacol， 2019， 10： 212.
［36］Garris CS， Wu L， Acharya S， et al. Defective sphingosine 1phosphate receptor 1 (S1P1) phosphorylation exacerbates TH17mediated autoimmune neuroinflammation［J］. Nat Immunol， 2013， 14(11)： 1166-1172.
|
| [1] |
. [J]. Journal of Jiangsu University(Medicine Edition), 2023, 33(02): 112-117. |
|
|
|
|
